top biopharmaceuticals for glp-1 medication Who are the leading innovators in analogues the pharmaceutical industry? Medicare will negotiate Novo's GLP-1

It also leans into expanding therapeutic uses and making sure treatment is more accessible, for more people

And yes, rapid urbanization, plus evolving lifestyle patterns, are also pushing demand up across the region

These companies currently offer five GLP-1 drugs approved for type 2 diabetes, with four also approved for various cardiovascular conditions

However, it can cause steatorrhea, resulting in fat-soluble vitamin deficiency, and can even cause liver damage

Since then, the landscape has seen numerous entries and exits, leaving Novo Nordisk and Eli Lilly as the primary players

The Phase III clinical SURMOUNT-1 (NCT04184622) for tirzepatide, is expected to be completed in the first half of 2024